glp 1 market share GLP-1 Receptor Agonist Size & Analysis, 2026-2033 GLP-1 Receptor Agonist Market: Exploring
Description
And obviously, a bit in the U.S
Semaglutide data is clear: when treatment stops, weight regain begins
Both HRS-9531 and MET-097 I think have a chance to help break the duopoly into smaller pieces, but itll still take until probably 2027 at the absolute earliest to see this happen and even then itll be a drug not featured during this conference
The magnitude of prednisone's blood sugar effect depends on the dose and duration of treatment
In: Diabetologia
